Ideaya Biosciences' (IDYA) darovasertib plus crizotinib combination's overall data profile is "highly compelling" and data-to-date supports accelerated approval, Wedbush said in a Tuesday note.

The company plans to submit its new drug application for darovasertib in H2 and has announced alignment with the US Food and Drug Administration to review the NDA under the real-time oncology review program, Wedbush noted.

Outside of darovasertib, Wedbush said it is looking forward to a clinical update from ongoing Chinese studies investigating IDE849 by partner Jiangsu Hengrui at a medical conference in H2, as well as registrational trial initiations in 2027.

"We remain excited for the extensive clinical development across pipeline assets, as well as a nearing potential approval for darovasertib," Wedbush analysts said.

The brokerage maintained the company's outperform rating with a $58 price target.

Price: 28.01, Change: -0.89, Percent Change: -3.08